Egis Pharmaceuticals made a net profit of HUF 18,531 mil with revenues of HUF 132,825 mil in 2012, up by 36.4% and up by 3.01%, respectively, compared to the previous year. This translates into a net margin of 14.0%.
Historically, between 2000 - 2012, the firm’s net profit reached a high of HUF 18,531 mil in 2012 and a low of HUF 5,540 mil in 2003. Since 2007, the firm's net profit has increased 143% or 19.4% a year on average.
On the operating level, EBITDA reached HUF 30,536 mil, up 19.2% compared to the previous year. Over the last five years, company's EBITDA has risen 15.9% a year on average.
As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter posted net and EBITDA margin of 15.1% and 23.1%, respectively in 2012, Krka generated margins of 14.0% and 24.5% and Sanofi-Aventis Czech Republic profit margin reached 0.626% on the net and 1.12% on the EBITDA level in 2019.
You can see all the company’s data at Egis Pharmaceuticals profile, or you can download a report on the company in the report section.
Helgi Library 
